150 related articles for article (PubMed ID: 26588255)
1. Cost-effectiveness analysis of a multivariate index assay compared to modified American College of Obstetricians and Gynecologists criteria and CA-125 in the triage of women with adnexal masses.
Forde GK; Hornberger J; Michalopoulos S; Bristow RE
Curr Med Res Opin; 2016; 32(2):321-9. PubMed ID: 26588255
[TBL] [Abstract][Full Text] [Related]
2. Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass.
Havrilesky LJ; Dinan M; Sfakianos GP; Curtis LH; Barnett JC; Van Gorp T; Myers ER
J Natl Cancer Inst; 2015 Jan; 107(1):322. PubMed ID: 25515232
[TBL] [Abstract][Full Text] [Related]
3. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses.
Coleman RL; Herzog TJ; Chan DW; Munroe DG; Pappas TC; Smith A; Zhang Z; Wolf J
Am J Obstet Gynecol; 2016 Jul; 215(1):82.e1-82.e11. PubMed ID: 26970494
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
7. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass.
Bristow RE; Hodeib M; Smith A; Chan DW; Zhang Z; Fung ET; Tewari KS; Munroe DG; Ueland FR
Am J Obstet Gynecol; 2013 Dec; 209(6):581.e1-8. PubMed ID: 23942039
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Fust K; Li X; Maschio M; Barron R; Weinstein MC; Parthan A; Walli-Attaei M; Chandler DB; Lyman GH
Gynecol Oncol; 2014 Jun; 133(3):446-53. PubMed ID: 24657302
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
Mehta DA; Hay JW
Gynecol Oncol; 2014 Mar; 132(3):677-83. PubMed ID: 24463160
[TBL] [Abstract][Full Text] [Related]
10. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
[TBL] [Abstract][Full Text] [Related]
11. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
[TBL] [Abstract][Full Text] [Related]
12. Guideline No. 403: Initial Investigation and Management of Adnexal Masses.
Salvador S; Scott S; Glanc P; Eiriksson L; Jang JH; Sebastianelli A; Dean E
J Obstet Gynaecol Can; 2020 Aug; 42(8):1021-1029.e3. PubMed ID: 32736853
[TBL] [Abstract][Full Text] [Related]
13. Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.
Cole AL; Barber EL; Gogate A; Tran AQ; Wheeler SB
Int J Gynecol Cancer; 2018 Jul; 28(6):1077-1084. PubMed ID: 29683880
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared With Abdominal Hysterectomy for Presumed Myomas.
Rutstein SE; Siedhoff MT; Geller EJ; Doll KM; Wu JM; Clarke-Pearson DL; Wheeler SB
J Minim Invasive Gynecol; 2016 Feb; 23(2):223-33. PubMed ID: 26475764
[TBL] [Abstract][Full Text] [Related]
16. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer.
Longoria TC; Ueland FR; Zhang Z; Chan DW; Smith A; Fung ET; Munroe DG; Bristow RE
Am J Obstet Gynecol; 2014 Jan; 210(1):78.e1-9. PubMed ID: 24055582
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients.
Eskander RN; Carpenter BA; Wu HG; Wolf JK
Curr Med Res Opin; 2016 Jun; 32(6):1161-5. PubMed ID: 27052730
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of alternative treatments for depression in low-income women.
Beil H; Beeber LS; Schwartz TA; Lewis G
J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
